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Background: Although cytotoxic T lymphocytes (CTLs) play a major role in eradicating cancer cells during
immunotherapy, the cancer-associated immunosuppressive microenvironment often limits the success of such
therapies. Therefore, the simultaneous induction of cancer-specific CTLs and reversal of the immunosuppressive
tumor microenvironment may be more effectively achieved through a single therapeutic vaccine. A recombinant
lipoprotein with intrinsic Toll-like receptor 2 (TLR2) agonist activity containing a mutant form of E7 (E7m) and a
bacterial lipid moiety (rlipo-E7m) has been demonstrated to induce robust CTL responses against small tumors. This
treatment in combination with other TLR agonists is able to eliminate large tumors.
Methods: Mouse bone marrow-derived dendritic cells (DCs) were employed to determine the synergistic
production of pro-inflammatory cytokines upon combination of rlipo-E7m and other TLR agonists. Antigen-specific
CTL responses were investigated using immunospots or in vivo cytolytic assays after immunization in mice. Mice
bearing various tumor sizes were used to evaluate the anti-tumor effects of the formulation. Specific subpopulations
of immunosuppressive cells in the tumor infiltrate were quantitatively determined by flow cytometry.
Results: We demonstrate that a TLR9 agonist (unmethylated CpG oligodeoxynucleotide, CpG ODN) enhances CTL
responses and eradicates large tumors when combined with rlipo-E7m. Moreover, combined treatment with rlipo-E7m
and CpG ODN effectively increases tumor infiltration by CTLs and reduces the numbers of myeloid-derived suppressor
cells (MDSCs), tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) in the tumor microenvironment.
Conclusion: These findings suggest that the dramatic anti-tumor effects of the recombinant lipoprotein together with
CpG ODN may reflect the amplification of CTL responses and the repression of the immunosuppressive environment.
This promising approach could be applied for the development of additional therapeutic cancer vaccines.
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Effective cancer immunotherapies should eradicate can-
cer cells and block the immunosuppression that occurs
in cancer microenvironments [1,2]. Although CTLs play
a major role in anti-tumor responses, increasing evi-
dence indicates that the induction of cytotoxic effects is
necessary, but not sufficient, to control tumor progres-
sion [3]. The function of CTLs is affected by systemic
and local immunosuppressive environments associated
with tumor growth. The lytic activity of CTLs in
the tumor microenvironment can be suppressed by
myeloid-derived suppressive cells (MDSCs), tumor-
associated macrophages (TAMs) and regulatory T cells
(Tregs) that surround the tumor [4-7]. Increasing the
number of MDSCs generates natural suppressive activ-
ity in cancer patients [8] and tumor-bearing mice [9],
and systemic accumulation of MDSCs is induced by
various factors associated with cancers and several
pathological conditions. In addition, CD4+CD25+ Tregs
increase at tumor sites in mice and humans during lung
[10], head and neck [11], breast [12] and ovarian can-
cers [13]. CD4+CD25+ Treg-depleting approaches have
revealed that reduced Treg numbers improve anti-
tumor responses and the inhibition of tumor growth
[14,15]. Accordingly, successful cancer immunotherapy
requires modulation of the immunosuppressive effects
of tumor-associated MDSCs, M2 macrophages and
Tregs.
Bacterial lipoproteins can be modified at the N-terminus
with di- or triacyl glyceryl-cysteine units, which are
recognized by TLR2 [16,17]. In addition to their TLR2
activity and their ability to induce dendritic cell matur-
ation, recombinant lipoproteins stimulate a cytokine
expression profile that is different from that of syn-
thetic lipopeptides [18]. We recently applied this plat-
form technology to produce a recombinant mutant
form of E7 (rlipo-E7m) to treat HPV-associated dis-
eases. We observed that the administration of rlipo-
E7m completely inhibited tumor growth [19]. In the
present study, we used the TLR9 agonist CpG ODN in
combination with rlipo-E7m to treat large tumors. Our
data indicate that the combination of rlipo-E7m and CpG
ODN dramatically eliminates large tumors. Moreover,
CpG ODN synergized with a TLR2 agonist–conjugated
antigen to induce the systemic and local production of
cytotoxic CD8+ T cells and decrease the number of
immunosuppressive cells both locally and systemically.
These findings suggest that CpG ODN combines with a
recombinant lipoprotein exhibiting TLR2 agonist activ-
ity to enhance anti-tumor immunity and block local
immunosuppressive cells. These results demonstrate
that the combination of CpG ODN and recombinant
lipoprotein represents a feasible approach for the
development of cancer vaccines.Results
Effects of CpG ODN with rlipo-E7m in DC activation and
tumor therapy
Previously, we demonstrated the ability of rlipo-E7m to
induce anti-tumor immunity [19]. However, we observed
that a low dose of rlipo-E7m (1 μg) did not inhibit tumor
growth (Figure 1a). To examine the therapeutic effects of
applying a multiple-dose regimen, tumor-bearing mice
were treated with 10 μg of rlipo-E7m with either two (days
14 and 21) or three injections (days 14, 21 and 28). As
shown in Figure 1b, multiple doses were ineffective in
controlling tumor growth. Moreover, a single-dose injec-
tion of 30 μg of rlipo-E7m 10 or 14 days after tumor
implantation delayed, but did not completely eradicate,
tumor growth (Figure 1c). This result suggests that add-
itional immune-potentiating signals must be incorporated
to eliminate large tumors.
In an attempt to increase DC activation with rlipo-
E7m, a TLR7 agonist (imiquimod) and a TLR9 agonist
(CpG ODN) were administered to evaluate the synergistic
effects of these compounds on plasmacytoid dendritic cells
(pDCs). Following stimulation of pDCs, administration of
rlipo-E7m combined with CpG ODN (rlipo-E7m/CpG)
substantially increased secretion of the pro-inflammatory
cytokines IL-12p70 and TNF-α, but no effect was observed
when rlipo-E7m was combined with imiquimod (Figure 2a).
Interestingly, secretion of the anti-inflammatory cytokine
IL-10 following CpG ODN stimulation was reduced under
combined treatment with rlipo-E7m (Figure 2a). Based on
these results, CpG ODN may be an effective adjuvant for
elevating the vaccine efficacy of the recombinant lipopro-
tein. Subsequently, a single injection of rlipo-E7m/CpG
resulted in tumor regression within 40 days of observation
(Figure 2b). Moreover, immunization with non-lipidated
E7m (rE7m), with or without CpG ODN, was also
conducted to determine whether lipidation (i.e., TLR2
stimulation) is indispensable for the observed elevated
therapeutic effects. We observed that immunization
with rE7m/CpG, but not rE7m alone, delayed tumor
growth (Figure 2b). These results suggested that the
combination of TLR2 agonist-fused antigen (rlipo-E7m)
and the TLR9 agonist (CpG ODN) induced strong anti-
tumor effects compared to antigen (rE7m) and CpG
ODN. Furthermore, suppression of tumor growth was
observed for over 100 days in response to treatment with
rlipo-E7m/CpG (Additional file 1: Figure S1a and S1b).
These data indicate that rlipo-E7m and CpG ODN
induced strong DC activation and the suppression of
tumor growth.
Treatment with rlipo-E7m and CpG ODN enhances
antigen-specific T cell immunity
To determine whether enhanced CTLs responses of rlipo-
E7m in vivo, spleen cells from immunized mice were used
Figure 1 Anti-tumor effects of rlipo-E7m. Approximately 2 × 105 TC-1 tumor cells were subcutaneously implanted into C57BL/6 mice. After 7 days,
the mice were subcutaneously injected with a single dose of (a) PBS, rlipo-E7m (1 μg/mouse) or rlipo-E7m (10 μg/mouse). The tumor-bearing mice
were administered 10 μg of rlipo-E7m at 14 days; 14 and 21 days; or 14, 21 and 28 days (b). A single dose of 30 μg of rlipo-E7m was subcutaneously
injected into the mice at 10 days or 14 days (c). The tumor volume was calculated using the formula length ×width ×width/2.
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immunizations at a 14-day interval, the rlipo-E7m/CpG-
mediated induction of E7-specific IFN-γ-secreting cells
(312.8 ± 88.98 per 1 million cells) was greater compared to
induction with rlipo-E7m alone (78.2 ± 24.6) (Figure 3a).
To quantify E7-specific CD8+ T cell numbers following
immunization, an MHC class I tetramer containing an
E7-derived H-2Db-restricted CTL epitope was used.
The proportion of E7-specific CD8+ T cells induced
through rlipo-E7m/CpG immunization was higher
(3.04% ± 1.24%) than that induced with rlipo-E7m alone
(0.29% ± 0.08%) (Figure 3b). To assess the cytolytic ef-
fects of these compounds in vivo, peptide-pulsed sple-
nocytes were labeled with different concentrations of
CFSE and subsequently injected (i.v.) into mice. The re-
sults indicate that immunization with rlipo-E7m/CpG
elicited a higher proportion of killing (62.26% ± 10.41%)
than rlipo-E7m immunization (39.8% ± 14.84%) (Figure 3c).
Similar results were observed when tumor-bearing mice
were immunized with rlipo-E7m/CpG (Additional file 2:
Figure S2a). E7-specific CD8+ T cell numbers were in-
creased ~60-fold following treatment with rlipo-E7m/CpGcompared to treatment with rlipo-E7m alone (Additional
file 2: Figure S2b). These results suggest that rlipo-E7m/
CpG induced strong CTL responses against these tumors.
Anti-tumor effects of rlipo-E7m and CpG ODN
Although it was evident that CpG ODN enhanced rlipo-
E7m-elicited cellular immunity in tumor-bearing mice,
the anti-tumor effects of this treatment against clinically
relevant tumors had not been determined. Thus, tumor-
bearing mice were treated with rlipo-E7m/CpG on day 7,
14 or 25. The sizes of their tumors were palpable, 0.6-0.8
cm and 1.0-1.2 cm on days 7 and 14 and day 25, respect-
ively. The tumors had completely regressed under treat-
ment with rlipo-E7m/CpG on days 7 and 14 (Figure 3d),
and tumor regression was also observed following
treatment with rlipo-E7m/CpG on day 25 (Figure 3d).
However, growth of the regressed tumors was observed
55 days post-tumor implantation, eventually killing the
mice. These findings indicate that rlipo-E7m/CpG could
be potentially used to treat large tumors. Furthermore,
when the tumor-free mice in the rlipo-E7m/CpG-treated
group were rechallenged with TC-1 tumor cells 135 days
Figure 2 TLR agonists synergistically enhance rlipo-E7m-induced dendritic cell activation and anti-tumor activity. Cultured plasmacytoid
dendritic cells (pDCs) were incubated with medium, CpG ODN (100 nM), imiquimod (10 μg/ml) or rlipo-E7m (100 nM) ± CpG ODN or imiquimod.
The supernatants were collected for the detection of cytokines 24 hours after stimulation. (a) Cytokines, including IL-12p70, TNF-α and IL-10, were
analyzed by ELISA to assess pDC activation. The data are presented as the means + SD of duplicate DC cultures from three independent experiments.
**P < 0.01, ***P < 0.001. (b) To evaluate the anti-tumor effect of the combined formulation, tumor-bearing mice were administered a single dose of PBS,
rE7m (1 μg/mouse), rE7m (1 μg/mouse) and CpG (10 μg/mouse), rlipo-E7m (1 μg/mouse) or rlipo-E7m (1 μg/mouse) and CpG ODN (10 μg/mouse) via
subcutaneous (s.c.) injection 7 days after tumor cell implantation. The tumor volume was calculated using the formula length ×width ×width/2(mm3).
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after 100 days (Additional file 3: Figure S3). These data
demonstrate that anti-tumor memory is generated by
immunization with rlipo-E7m/CpG. To assess the thera-
peutic effects in a lung metastasis model, cancer cells were
inoculated intravenously. A single-dose injection of PBS,
rlipo-E7m, CpG or rlipo-E7m/CpG was administered 14
days after tumor inoculation, and only rlipo-E7m/CpG
effectively protected the mice. The survival rate 100 days
after tumor implantation was 70% in the rlipo-E7m/CpG-
treated group (Figure 3e).
Because the large tumor did not completely regress after
a single treatment with rlipo-E7m/CpG, a combinationwith chemotherapy may improve the therapeutic effects.
To increase the efficiency of tumor growth inhibition for
further immunotherapy, the chemotherapy drug cisplatin
was administered four days before immunization. The
survival rate of tumor-bearing mice was increased when
cisplatin was combined with rlipo-E7m/CpG (Figure 3f).
These data further demonstrate that the administration of
rlipo-E7m/CpG and cisplatin prolongs the survival time of
mice.
To exclude the possibility that this anti-tumor activity
reflected non-specific activation of TLR2 (rlipo-E7m)
and TLR9 (CpG ODN) in antigen-presenting cells, mice
were implanted with another type of tumor cell (EL-4,
Figure 3 Immunization with rlipo-E7m and CpG ODN elicits antigen-specific CTL responses and robust anti-tumor effects against large
tumors. Mice were immunized s.c. with rlipo-E7m (10 μg/mouse) with or without CpG (10 μg/mouse) and were boosted once 14 days after the
first immunization. The mice were euthanized 7 days after the second immunization. (a) The isolated spleen cells were re-stimulated with 10 μg/ml of
HPV16E749-57 (RAH)-specific peptide (SP) or non-specific peptide (OVA257-264) (NP) for 48 hours, and IFN-γ production was determined using the ELISPOT
assay. The data represent the number of IFN-γ spot-forming cells per 106 spleen cells for each duplicate (means + SD). (b) The spleen cells were stained
with the RAH/MHC I tetramer and anti-CD8 antibody. (c) Naïve spleen cells were pulsed with SP or NP and then stained with 5 μM CFSEhi or 0.5 μM
CFSElo, respectively. The CFSE-labeled cells were i.v. injected into immunized micefor 18 hours, and analyzed by flow cytometry. Specific lysis
was determined using the following equation: % specific lysis = [1-(% CFSEhi /% CFSElo)] × 100. (d) Tumor-bearing mice were immunized with
rlipo-E7m (10 μg/mouse) and CpG (10 μg/mouse) at 7, 14 or 25 days post-TC-1 cell (2 × 105) implantation, and PBS was used as a control. The
tumor volume was calculated using the formula length × width × width/2. (e) The mice were injected with 2 × 105 TC-1 cells intravenously.
After 14 days, the mice were injected with PBS, rlipo-E7m, CpG or rlipo-E7m/CpG subcutaneously. (f) Tumor-bearing mice were immunized s.c.
with rlipo-E7m in the presence or absence of CpG 25 days following cisplatin (75 μg/mouse) treatment (day 21). Kaplan-Meier analysis was
performed on the survival data. (*P < 0.05, **P < 0.01, ***P < 0.001).
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ODN. Anti-tumor effects were not observed in the EL-4
tumor-bearing mice (Additional file 4: Figure S4). Taken
together, these results suggest that antigen-specific anti-
tumor immunity associated with rlipo-E7m is substan-
tially enhanced by CpG ODN.
Anti-tumor effects of rlipo-E7m and CpG ODN depend on
CD8+ T cells and TLR9
Although rlipo-E7m alone induces CD8-dependent anti-
tumor effects, these effects may differ in the presence of
CpG ODN [19]. We treated tumor-bearing mice (7 days)
with single i.p. injections of anti-CD8, anti-CD4 or
control antibodies (rat IgG) before immunization with
rlipo-E7m/CpG. Tumor regression was observed in
mice treated with anti-CD4 or rat IgG (Figure 4a). In
contrast, the anti-tumor effects were blocked by treat-
ment with anti-CD8. The tumor growth in mice treatedwith anti-CD8 was similar to the growth observed
in mice that were not treated with rlipo-E7m/CpG
(Figure 4a). Furthermore, NK cells can be activated or
recruited for priming CTL responses by CpG ODN
[20]. As seen in Figure 4b, the depletion of NK cells did
not block the anti-tumor effects of rlipo-E7m/CpG, and
tumor regression was similar to what was observed in
the mice treated with control mouse IgG antibody.
These data suggest that CpG ODN increased the CD8-
mediated anti-tumor effects of rlipo-E7m. To clarify
whether TLR9 is necessary for the anti-tumor effects of
rlipo-E7m/CpG, tumor-bearing TLR9-knockout mice
were treated with PBS, rlipo-E7m or rlipo-E7/CpG. The
anti-tumor effects of rlipo-E7m/CpG were lost in the
TLR9-knockout mice (Figure 4c). These results demon-
strate that the anti-tumor effects of rlipo-E7m plus CpG
ODN were the result of contributions from both CD8+
T cells and TLR9 signaling.
Figure 4 Anti-tumor effects of rlipo-E7m/CpG are mediated by CD8+ T cells and TLR9 signaling. C57BL/6 mice (n = 6 per group) were
implanted s.c. with 2 × 105 TC-1 tumor cells. Tumor-bearing mice were immunized with PBS or rlipo-E7m/CpG (10 μg/mouse) s.c. 14 days post-tumor
cell implantation. (a) Mice were i.p. injected with 0.5 mg of anti-CD4, anti-CD8 or rat IgG one day before immunization. (b) Mice were i.p. injected with
anti-NK1.1 antibody or mouse IgG one day before immunization. (c) TLR9-KO mice were implanted s.c. with 2 × 105 TC-1 tumor cells. Tumor-bearing
mice were immunized with rlipo-E7m (1 μg/mouse) and CpG (10 μg/mouse) via s.c. injection day 7 post-TC-1 cell implantation. The data show the
individual tumor volume after tumor cell implantation. The numbers of mice for each group are indicated in each graph. Tumor volume was calculated
by the formula: length ×width ×width/2(mm3).
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immune regulators in tumor-bearing mice
In the last decade, tumor-induced immunosuppressive
factors and cells in the tumor microenvironment have been
identified as major obstacles for cancer immunotherapy.
Accordingly, investigation into the effects of rlipo-E7m/
CpG immunization on the inhibition of immunosup-
pressive cells is of interest. Therefore, we attempted to
distinguish the systemic and local immunosuppressive
cell populations in mice following treatment with rlipo-
E7m or rlipo-E7m/CpG. The administration of rlipo-E7m
or rlipo-E7m/CpG did not affect the frequency of splenic
Tregs in tumor-free mice (Figure 5a). rlipo-E7m or rlipo-
E7m/CpG was administered to tumor-bearing mice 14
days after tumor implantation (size was 0.6-0.8 cm in
diameter). At 21 or 25 days after tumor implantation,
splenic Tregs (CD4+CD25+FoxP3+) were analyzed. The
Treg population was reduced by the administration of
rlipo-E7m (~13%) or rlipo-E7m/CpG (~12%) 25 days
post-tumor implantation compared to the control group
(~19%) (Figure 5b). In addition, the frequency of MDSCs
was similar among naïve mice in each group (~2%)
(Figure 5c). In tumor-bearing mice, the MDSC popula-
tion increased from ~2% to 7.2% and 17.9% on days 25
and 30, respectively (Figure 5d). Surprisingly, the fre-
quency of MDSCs was reduced to 4.6% and 5.8%
following treatment with rlipo-E7m at days 25 and 30,
respectively (Figure 5d). Moreover, the administration
of rlipo-E7m/CpG completely suppressed the expan-
sion of splenic MDSCs (2.6% and 2.6% on average by
days 25 and 30, respectively; Figure 5d). These results
indicate that immunization with rlipo-E7m or rlipo-E7/CpG systemically reduces the frequency of both
Tregs and MDSCs in tumor-bearing mice.
To further verify the frequencies of immunosuppressive
cells in the tumor microenvironment, tumor tissues were
processed and stained for markers of MDSCs, Tregs and
TAMs. As shown in Figure 6a, the frequency of tumor-
infiltrating MDSCs was suppressed by treatment with
rlipo-E7m/CpG (7.06% ± 3.76%) but not by treatment
with rlipo-E7m (25.33% ± 4.91%) or CpG ODN alone
(Figure 6a). Accordingly, the number of Tregs was also
considerably reduced by rlipo-E7m/CpG (10.67% ± 2.17%)
treatment but not by treatment with rlipo-E7m (37.41% ±
10.44%) or CpG (30.54% ± 20.69%) compared to the con-
trol (33.32% ± 12.49%) (Figure 6b). Interestingly, the TAM
population was reduced following treatment with rlipo-
E7m/CpG (15.22% ± 8.7%) or CpG (29.1% ± 20.42%) but
not after treatment with rlipo-E7m alone (49.56% ± 9.58%)
(Figure 6c). Because TAMs can be divided into the inflam-
matory M1 type (TNF-α+/IL-12+/iNOS+/CD80+) and the
immunosuppressive M2 type (IL-10+/TGF-β+Arginase I+)
[21], the M1/M2 TAM ratio was calculated. The M1/M2
ratio was increased when tumor-bearing mice were treated
with rlipo-E7m/CpG but not with rlipo-E7m or CpG
alone (Figure 6d). The concentration of the co-stimulatory
molecule CD80 was significantly up-regulated on TAMs
following treatment with rlipo-E7m or rlipo-E7m/CpG
but not after treatment with CpG alone (Figure 6e). These
findings imply that rlipo-E7m/CpG increases the number
of M1-like TAMs. These data also demonstrate that rlipo-
E7m reduces the numbers of immunoregulatory cells in
circulation and in the tumor microenvironment in the
presence or absence of CpG ODN.
Figure 5 The combination of rlipo-E7m and CpG leads to the suppression of systemic immunosuppressive cells in tumor-bearing mice.
TC-1 tumor-bearing mice (n = 3 per group) or naïve mice (n = 6 per group) were immunized with rlipo-E7m (10 μg/mouse), rlipo-E7m (10 μg/
mouse) + CpG (10 μg/mouse) or PBS as a control. (a) Splenic CD4+CD25+FoxP3+ Treg cells derived from immunized tumor-free mice were
quantified by flow cytometry 7 days after immunization, and (b) cells from tumor-bearing mice were analyzed 21 and 25 days after tumor
implantation. The data represent the percentage of splenic Treg cells and are shown as the means + SD. (c) Splenic CD11b+Gr-1+ (MDSCs) cells
derived from immunized tumor-free mice were quantified by flow cytometry 7 days after immunization, and (d) the MDSCs from tumor-bearing
mice were analyzed 25 and 30 days after tumor implantation. The data represent the percentage of splenic MDSCs and are shown as the means + SD.
*P < 0.05, **P < 0.01, ***P < 0.001.
Chang et al. Molecular Cancer 2014, 13:60 Page 7 of 13
http://www.molecular-cancer.com/content/13/1/60Discussion
The limited success of cancer immunotherapy reflects
the induction of CTL responses that cannot eliminate
cancer cells in the presence of tumor-infiltrated immuno-
suppressive cells (i.e., MDSCs, Tregs and M2 macrophages).
To develop a new generation of immunotherapeutic ap-
proaches, the enhancement of CTL responses and reduc-
tion of immunosuppressive cell numbers must be induced
simultaneously. We recently developed rlipo-E7m, which
possesses TLR2 agonist activity and robust CD8-mediated
anti-tumor activity against palpable tumors in the absence
of exogenous adjuvants [19]. In clinical situations, immu-
notherapeutic reagents must eliminate large tumors and
overcome the immunosuppressive barriers of the tumor
environment. In this report, we demonstrate that rlipo-
E7m alone could not inhibit the growth of large tumors
following a single-dose treatment. Although multipledoses did eliminate tumors in some mice, rlipo-E7m in
the presence of CpG ODN dramatically eliminated large
tumors. In addition, the numbers of tumor-associated
immunosuppressive cells, including MDSCs, Tregs and
TAMs (especially M2-like cells), were decreased follow-
ing treatment with rlipo-E7m/CpG. These results dem-
onstrate that rlipo-E7m/CpG not only induces strong
CTL responses but also modulates tumor-associated
immunosuppressive cells. The synergistic TLR-mediated
stimulation of DCs increases the production of inflam-
matory cytokines and promotes Th1-polarized immunity,
which drives CTL responses [22,23]. The combination
of TLR3 and TLR9 stimulation enhances the priming
efficiency of a DNA vaccine [24]. TLR2/TLR3 agonists
or TLR3/TLR9 agonists synergistically activate DCs and
subsequently increase the number of activated T cells [25].
These results indicate that high-quality CTL responses are
Figure 6 The combination of rlipo-E7m and CpG leads to the suppression of immunosuppressive cells in the local tumor environment.
Tumor-bearing mice (n = 6 per group) were immunized with rlipo-E7m (10 μg/mouse), rlipo-E7m (10 μg/mouse) + CpG (10 μg/mouse) or PBS as
a control 14 days post-tumor cell implantation. The tumors removed from the tumor-bearing mice 24 days post-implantation were minced and
crushed through a 70-μm filter, and the total cells were stained with antibodies against the indicated markers; 50,000 events were acquired for
each sample. The data represent the percentage of the indicated markers for individual animals. Comparison of the (a) MDSC (Gr-1+ CD11b+),
(b) Treg (CD4+ CD25+ FoxP3+), (c) TAM (F4/80+ CD11b+), (d) TNF-α+ TAM/IL-10+ TAM and (e) CD80+ TAM cell populations. Significant differences
are indicated by the P values in the graph.
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TLRs also reduce the immunosuppressive activity of
MDSCs [26], TAMs [27,28] and Tregs [29,30].
Although the synergistic activation of DC and T cell re-
sponses through multiple TLR agonists has been reported
[22,25,31,32], these synergistic effects are not observed
when combinations of TLR2 and TLR9 agonists are used
[25,32]. Similar results were obtained when rlipo-E7m
(a TLR2 agonist) was combined with a TLR9 agonist to
stimulate bone marrow-derived DCs (Additional file 5:
Figure S5). However, synergistic activation was detected
when plasmacytoid DCs were used (Figure 2a). We fur-
ther measured TLR2 and TLR9 transcripts in different
DC subsets and found that the expression of TLR9 was
higher in pDCs than in BMDCs or splenic DCs. How-
ever, the expression of TLR2 was higher in BMDCs than
in pDCs or splenic DCs (Additional file 6: Figure S6).
We suggest that the synergistic effects of rlipo-E7m andCpG may be due to the balance of TLR2 and TLR9
expression in pDCs. Moreover, antigen-specific CD8+ T
cell responses were not improved when the HIV Env-
derived peptide (KQIINMWQEVGKAMYAPPISGQIR-
RIQRGPGRAFVTIGK) was mixed with both TLR2 and
TLR9 agonists [32]. In contrast, immunization with the
TLR2 agonist-fused antigen (rlipo-E7m) substantially
increased CTL responses in the presence of the TLR9
agonist (Figure 3). These conflicting results may result
from the lipid moiety of rlipo-E7m, which contains an
unsaturated fatty acid, or the fact that rlipo-E7m effi-
ciently co-delivers both antigen and TLR2 agonists to
antigen-presenting cells, and the TLR9 agonist might
enhance the cross-presentation of antigen to CD8+ T
cells. We also found that rlipo-OVA/CpG-pulsed pDCs
induced higher T cell proliferation than rlipo-OVA alone
(Additional file 7: Figure S7a). The rlipo-OVA/CpG-pulsed
BMDCs did not induce higher T cell proliferation than
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it would be nice if the combination could be reproduced
in a different antigen model. We produced a model anti-
gen recombinant lipo-ovalbumin (rlipo-OVA) and mea-
sured its therapeutic effects with CpG (Additional file 7:
Figure S7b). We found that rlipo-OVA/CpG had stronger
anti-tumor effects in EG7 (ovalbumin-expressing cell
line)-bearing mice than rlipo-OVA alone. These results
indicate that TLR9 agonists enhance antigen presentation
of TLR2 agonist-fused antigens to CD8+ T cells.
In addition to the dramatic anti-tumor effects of rlipo-
E7m/CpG, the inhibition of local immunosuppressive cells
was also observed following this combined treatment.
CpG administration induces differentiation and blocks the
immunosuppressive function of MDSCs [26,33] and Tregs
[34]. Our results also indicate that the administration
of CpG alone mildly reduced the numbers of tumor-
infiltrating MDSCs and TAMs. Interestingly, the ad-
ministration of rlipo-E7m/CpG significantly improved
the reduction of immunosuppressive cell numbers com-
pared to treatment with CpG alone (Figure 6). In tumor-
bearing mice, a high percentage of M2-like TAMs was
detected among tumor-infiltrating leukocytes. This ob-
servation is consistent with a previous report indicating
that the depletion of TAMs promotes the infiltration of
lymphocytes [35]. We observed that treatment with
rlipo-E7/CpG enhanced the number of M1-like TAMs
and reduced the number of M2-like TAMs (Figure 6 c, d).
Interestingly, CD80+ TAM numbers were dramatically in-
creased in the rlipo-E7m/CpG group. CD80+ TAMs have
an M1-like phenotype that produces Th1-biased cytokines
for M1 polarization [36,37]. Furthermore, CD80 is a
co-stimulatory molecule in antigen-presenting cells that
provides the second signal for priming T cells. Switching
of tumor-infiltrating macrophages from M2 to M1 has
been reported upon use of a combination of CpG ODN
and anti-IL-10 antibodies to suppress tumor growth
[38]. Here, our data further indicate that rlipo-E7m/
CpG significantly increases the number of antigen-specific
CD8+ T cells during tumor infiltration (Additional file 8:
Figure S8). Reduction of the number of TAMs or im-
munosuppressive cells may not completely eradicate
tumor growth; thus, local cytotoxic T lymphocytes are
critical for killing tumor cells. The numbers of local
CD8+ T cells and antigen-specific CD8+ T cells were
significantly increased in the tumor microenvironment
(Additional file 8: Figure S8). We speculate that these
infiltrating CD8+ T cells might secrete IFN-γ or other
cytokines to shift from the M2 to the M1 phenotype.
Although we observed that systemic administration of
CpG ODN alone did not induce anti-tumor effects or
reduce immunosuppressive cell numbers, CpG ODN
may amplify the effects of rlipo-E7m and efficiently
eliminate large tumors. Therefore, our findings suggestthat the induction of CTL responses and the reduction
of immunosuppressive cell numbers are critical for
eliminating large tumors.
In conclusion, a single administration of recombinant
lipoprotein induced strong anti-tumor immunity in the
presence of a TLR9 agonist. Anti-tumor immunity re-
sulted from the induction of antigen-specific CD8+ T cells
and the reduction of immunosuppressive cells in the
tumor microenvironment. Currently, we are investigating
the potential critical cells and cytokines involved in the
local inhibition of immunosuppressive cells.
Materials and methods
Animals, cell line and reagents
C57BL/6 mice were purchased from the National La-
boratory Animal Center, Taiwan. TLR9-KO mice were
purchased from Oriental Bioservice, Inc. (Tokyo, Japan).
All experimental mice were maintained in a pathogen-free
environment at the Laboratory Animal Center of the
National Health Research Institutes (NHRI). The ani-
mals were used in compliance with institutional animal
health care regulations, and all animal experimental
protocols were approved by the NHRI Institutional Ani-
mal Care and Use Committee. For experimentally induced
neoplasia in mice, the allowable tumor burden and criteria
for euthanasia complied with the NCI Frederick ACUC
Guidelines (Involving Experimental Neoplasia Proposals
in Mice and Rats, 2006). Tumor survival was determined
based on 20% weight loss, unexpected moribundity or an
inability to obtain food or water.
The TC-1 cell line expressing the HPV-16 E6 and E7
oncoproteins was a kind gift from Dr. T-C. Wu (Johns
Hopkins University, USA) [39]. The cells were grown in
RPMI-1640 medium supplemented with 10% (v/v) fetal bo-
vine serum, 50 units/mL penicillin/streptomycin, 0.5 mM
sodium pyruvate, 20 mM HEPES (Biological industries,
Beit Haemek, Israel) and 0.5 μM β-mercaptoethanol at
37°C under 5% CO2.
Oligodeoxynucleotide 1668 (CpG-ODN) was purchased
from Invitrogen (Grand Island, NY). Its sequence was
5′-TCC ATG ACG TTC CTG ACG TT-3′ with a phos-
phorothioate backbone. Recombinant mouse GM-CSF
and FLT-3 ligand were purchased from PeproTech, and
lipopolysaccharide (LPS; Escherichia coli endotoxin
serotype 055:B5) was purchased from Sigma-Aldrich. Car-
boxyfluorescein diacetate succinimidyl ester (CFSE) and
propidium iodide (PI) were purchased from Invitrogen™.
The PE-conjugated HPV16E749-57/MHC I tetramer was
purchased from Beckman Coulter, Inc. The antibodies
used in this study, with their respective clones in paren-
theses, were anti-CD16/32 (2.4G2), anti-CD4 (GK1.5),
anti-CD8 (53-6.7), anti-F4/80 (BM8), anti-Gr-1 (RB6-
8C5), anti-CD11b (M1/70), anti-IFN-γ (XMG1.1), anti-
TNF-α (MP6-XT22), anti-IL-10 (JESS-16E3), anti-Foxp3
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CD45 (EM-05) (GeneTex, Inc). The chemotherapy drug
cisplatin was purchased from Sigma Aldrich®.Generation of dendritic cell subsets
The pDCs were derived from C57BL/6 mouse bone
marrow [40]. Briefly, the tibias were removed from 6-
12-week-old mice and rinsed in 75% ethanol. The bone
marrow cells were then flushed out and passed through
a 70-μm nylon cell strainer (BD Falcon) with lymphocyte
culture medium (LCM, RPMI-1640 medium supple-
mented with 10% (v/v) fetal bovine serum, 50 units/mL
penicillin/streptomycin, 20 mM HEPES and 0.5 μM
β-mercaptoethanol). After centrifugation at 1,200 rpm
for 10 minutes, the bone marrow cells were lysed in 3 mL
of RBC lysis buffer (BioLegend®) for 3 minutes, and 10 mL
of LCM was added to halt the lysis. The cells were again
centrifuged at 1,200 rpm for 10 minutes, and the cell
supernatant was discarded. The cells were subsequently
resuspended in LCM, and 2 × 106 cells were seeded into a
90 × 15 mm Petri dish (α-Plus) with 10 mL of LCM as
well as 100 ng/mL of FLT-3 ligand (PeproTech) or 20 ng/
ml of GM-CSF (PeproTech). The cells were incubated at
37°C under 5% CO2 for 3 days, and another 10 mL of
LCM containing 100 ng/mL of FLT-3 ligand or 20 ng/ml
of GM-CSF was added to the cell culture plates (day 7,
CD11c+ cells ~75%). The floating BMDCs or pDCs were
harvested on day 6 or day 7, respectively, and 2 × 105 DCs
were seeded into a 96-micro-well plate with 0.1 mL of
LCM. The stimulating ligand was dissolved in LCM and
subsequently added to the DC culture for an additional 24
hours of incubation. For the DC activation analysis, sev-
eral secretory cytokines in the culture supernatants were
detected by ELISA. All assays were performed in duplicate
in three independent experiments.Immunization and tumor challenge
To evaluate therapeutic anti-tumor effects, TC-1 cells (2 ×
105 per mouse) were implanted subcutaneously into the
left flanks of naïve C57BL/6 mice 7, 14 or 25 days prior to
immunization. The mice were arbitrarily assigned to
groups (6 per group) and were immunized subcutaneously
in the dorsum with the indicated doses of rlipo-E7m [19],
either alone or as an admixture with 10 μg of CpG ODN,
in a total volume of 100 μL in PBS for each mouse. To
monitor tumor growth, the tumors were measured with
electronic calipers three times weekly. The tumor volume
was calculated using the formula length x width2 × 1/2.
TC-1 cancer cells (2 × 105) were inoculated into
C57BL/6 mice by intravenous injection to establish an
experimental animal model of metastatic lung cancer
[41]. After 14 days, a single dose of PBS, rlipo-E7m,
CpG or rlipo-E7m/CpG was subcutaneously injectedinto the mice to evaluate the therapeutic effects of these
compounds.
ELISPOT assay
The IFN-γ ELISPOT assay was performed according to
the manufacturer’s instructions (eBioscience). Briefly, the
ELISPOT plate (MSIP, Millipore) was pre-coated with
anti-mouse IFN-γ capture antibody (AN18) overnight and
subsequently blocked with LCM at room temperature for
2 hours. Splenocytes (1 × 106 per well) were plated in
duplicate along with an H2-Db-restricted CTL epitope
(HPV16E749-57) at a concentration of 10 μg/mL or with
control peptides at 37°C for 48 hours. Following incuba-
tion, the plates were washed and incubated with biotinyl-
ated anti-mouse IFN-γ detection antibody (R46A2) for 2
hours, followed by incubation with avidin-HRP for 30 mi-
nutes and color development with AEC substrate reagents
according to the manufacturer’s instructions (Sigma).
Flow cytometry
To characterize the populations of myeloid-derived sup-
pressor cells (MDSCs), regulatory T cells (Tregs) and
tumor-associated macrophages in immunized mice, RBC-
lysed splenocytes or tumor cells derived from tumor-free
and/or tumor-bearing mice were incubated with an anti-
CD16/CD32 antibody to block non-specific binding and
were subsequently stained with fluorochrome-conjugated
monoclonal antibodies for surface marker and intracellular
staining according to the manufacturer’s instructions
(eBioscience®). Briefly, the cell suspension was stained with
FITC-conjugated anti-CD4, PE-conjugated anti-CD25 and
PE-Cy5-conjugated anti-Foxp3 to quantify Tregs; PE-
conjugated anti-CD11b and PE-Cy7-conjugated anti-
Gr-1 to quantify MDSCs; FITC-conjugated anti-F4/80
and PE-conjugated anti-CD11b to quantify TAMs and
APC-conjugated anti-CD45 to quantify tumor-infiltrating
leukocytes. For the intracellular detection of IFN-γ-
secreting CD8+ T cells, RBC-lysed splenocytes derived
from immunized C57BL/6 mice were re-stimulated with
10 μg/mL of H2-Db-restricted CTL epitopes (HPV16 E749-57)
for 48 hours. The cells were subsequently harvested and
stained with FITC-conjugated anti-CD8 and PE-conjugated
anti-IFN-γ using a standard intracellular protocol. The
E7-specific CD8+ T cells were stained with a PE-conjugated
H-2Db/RAH tetramer and FITC-conjugated anti-CD8. The
percentage of H-2Db/RAH+ CD8+ T cells was determined
by flow cytometry (FACSCalibur, BD Bioscience, San Jose,
CA). All of the data were analyzed using a FACSCalibur
flow cytometer and the CellQuest software. All analyses
were conducted on a gated lymphocyte population.
In vivo cytolytic assay
To detect antigen-specific cytolytic activity in the immu-
nized mice in vivo, specific or irrelevant peptide-pulsed
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killing assay. The RBC-lysed splenocytes were counted
and divided into two equal portions. These two portions
were incubated at a density of 2 × 107 cells/ml with a
specific peptide (HPV16 E749-57) and a non-specific peptide
(OVA257-264) at 37°C for 30 minutes. To differentiate be-
tween the peptide-pulsed target cells, the two subsets of
cells were labeled with CFSEhi (5 μM) and CFSElo (0.5 μM)
at 37°C for 10 minutes. Both samples of cells were resus-
pended at 2 × 107 cells/ml and subsequently mixed at a 1:1
ratio (1 × 107:1 × 107) in PBS prior to adoptive transfer into
immunized mice via tail vein injection 7 days after the pre-
vious immunization. The experimental cells were harvested
18 hours after adoptive transfer and analyzed using a
FACSCalibur flow cytometer (BD Bioscience). The per-
centage of specific lysis was calculated using the following
equation: % Specific lysis = [1-(%CFSE hi/%CFSE lo)] × 100.
Depletion of leukocyte subpopulations in vivo
CD4+, CD8+ or NK cells were depleted in vivo using 0.5
mg of anti-CD4 (GK1.5, eBioscience®), anti-CD8 (53-6.7,
eBioscience®) or anti-NK1.1 (PK136, BioLegend®) injected
intraperitoneally into mice one day prior to immunization.
Rat IgG or mouse IgG (0.5 mg) (Invitrogen™) was used as
the control antibody. The depletion efficiency was ~90%
as determined by flow cytometry. Mice were implanted
with TC-1 cells (2 × 105 per mouse) subcutaneously. Seven
days later, 10 μg of rlipo-E7m/CpG was injected s.c. into
the dorsum in a total volume of 100 μL. To monitor
tumor growth, the tumors were measured with electronic
calipers three times weekly. The tumor volume was calcu-
lated using the formula length × width2 × 1/2.
Statistical analysis
Statistical analyses were performed using Prism version
5.02 (GraphPad, CA, USA). Kaplan-Meier analysis was
performed on the survival rates of the mice. The statistical
significance of the differences between the groups was
assessed using a two-tailed Student’s t test. For all results,
P < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. rlipo-E7m induced long-lasting anti-tumor
effects in the presence of CpG ODN. A total of 2 × 105 TC-l tumor cells were
s.c. implanted into C57BL/6 mice. At 7 days post-tumor cell implantation,
tumor-bearing mice were administered a single dose of (a) PBS or (b) rlipo-
E7m (10 μg/ mouse) + CpG via s.c. injection. The data represent the
individual tumor volume over time following tumor cell implantation. All
tumors were measured at regular intervals using electronic calipers The mice
were euthanized when the tumor diameter reached 20 mm or when
necessary due to the moribund status of the animals. The numbers of mice
in each group are indicated in each graph. The tumor volume was
calculated using the formula length × width × width/2 (mm3).
Additional file 2: Figure S2. Induction of CTL responses in tumor-
bearing mice. (a) CFSE-labeled cells were i.v. injected into tumor-bearingmice (n=6 per group) 10 days after immunization. After 18 h, spleen cells
were isolated from immunized mice and analyzed via flow cytometry.
(b) The tumor cells were stained with an RAH/MHC I tetramer and
anti-CD8 antibodies. The data represent the percentage of CD8+RAH Tet+
in all cells. *P < 0.05, **P < 0.01, ***P < 0.001.
Additional file 3: Figure S3. rlipo-E7m induced long-lasting memory of
anti-tumor effects. After treatment with rlipo-E7m/CpG, the tumor-free mice
(n=9) were re-challenged with TC-L cells (2 × 105/mouse) subcutaneously at
135 days (naive mice were used as a control). Kaplan-Meier analysis was
performed on the mice survival data (***P < 0.001, naive versus rlipo-E7m/
CpG). Tumor survival was determined based on 20% weight loss,
unexpected moribundity or an inability to obtain food or water (as
described in Materials and Methods).
Additional file 4: Figure S4. rhpo-F7m- and CpG ODN-mediated
therapeutic effects are abolished in thymoma tumor-bearing mice. A
total of 5 × 104 EL4 tumor cells were subcutaneously (s.c.) implanted into
C57BL/6 (n=5 per group) mice. Seven days after tumor cell implantation, the
tumor-hearing mice were administered a single dose of PBS, rlipo-E7m or
rlipo-F7m + CpG via s.c. injection The data represent the mean tumor
volume at 17, 24 and 27 days after tumor cell implantation (means + SD). All
the tumor sizes were measured using electronic calipers and calculated
using the formula length × width × width/2 (mm3).
Additional file 5: Figure S5. The combination of the recombinant
lipoprotein and CpG ODN shows no synergistic effects on BMDCs
activation. Mouse bone marrow-derived BMDCs at 6 days after GM-CSF
supplementation were used to the evaluate synergistic effects of innate
immune cell activation induced through rlipo-E7m in combi nation with
CpG ODN, The BMDC supernatants were collected for cytokine detection
at 24 h after stimulation. The cytokines IL-l2p7O, TNF- α, IL-6 and IL-10
were analyzed through ELISA to assess the extent of DCs activation. The
presented data represent the mean + SD of duplicate BMDCs cultures
from three independent experiments.
Additional file 6: Figure S6. Expression of TLR2 and TLR in dendritic
cell subsets. Total RNA of BMDCs, pDCs or splenic DCs were extracted
using the total RNA isolation kit. The obtained cDNA was diluted 1/25
with water and 10 μL were used for amplification. The PCR was
performed with the SYBRR Green PCR Master Mix. Gene expression of
TLR 2 and TLR 9 was determined by quantitative real-time RT-PCR and
normalized to GAPDH.
Additional file 7: Figure S7. TLR9 agonist CpG enhanced anti-tumor
effects and antigen presentation of recombinant lipoimmunogen. (a) BMTCs
or pDCs were pulsed with rlipo-OVA( 100 nM) in the presence or absence of
CpG (100 nM) for 18 hr. Purity > 90% The CD8+ cells isolated from OT-l mice
(purity > 90%) were cultured with protein-plused DCs in the ratio 5:1 for
72 hr. T cell proliferation was determined by [3H] -thymidine incorporation.
(b) C57BL/6 mice (n=6 per group) were inoculated with 2 ×l04 of EG7 cells
in a total volume 200 μ1 subcutaneously. After 3 days, 10 μg of rOVA, rlipo-
OVA, rlipo-OVA/CpG or PBS was injected s.c. Tumor growth was observed
three times per week. The tumor volume was shown as length × width ×
width/2 (mm3). Data are expressed as mean SEM.
Additional file 8: Figure S8. rlipo-E7m immunization leads to increased
numbers of tumor-infiltrating antigen-specific CD8+ T cells in the pres-
ence of CpG ODN. Tumor-bearing mice (n=6 per group) were immunized
with rlipo-E7m (10 μg/mouse), rlipo-E7m (10 μg/mouse) + CpG (10 μg/
mouse) or PBS as a control at 14 days post-tumor cell implantation. The
tumors removed from tumor-bearing mice at 24 days post-tumor im-
plantation were minced and crushed through a 70-μm filter, and the total
cells were stained with antibodies against the indicated markers 50,000
events were acquired for each sample The data represent the percentages
of (a) total CD8+ cells and (b) E7-specific CD8+ cells among tumor-infiltrating
CD45+ cells. Significant differences are indicated by the P values in the
graph.Abbreviations
TLR: Toll-like receptor; CTL: Cytotoxic T lymphocyte; CpG ODN: CpG
oligodeoxynucleotides; DC: Dendritic cell; pDC: Plasmacytoid dendritic cell;
MDSC: Myeloid-derived suppressor cell; Treg: Regulatory T cell; TAM: Tumor-
associated macrophage.
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